1. Defining changes in physical limitation from the patient perspective: insights from the VITALITY‐HFpEF randomized trial. (3rd April 2022) Authors: Butler, Javed; Spertus, John A.; Bamber, Luke; Khan, Muhammad Shahzeb; Roessig, Lothar; Vlajnic, Vanja; Norquist, Josephine M.; Anstrom, Kevin J.; Blaustein, Robert O.; Lam, Carolyn S.P.; Armstrong, Paul W. Journal: European journal of heart failure Issue: Volume 24:Number 5(2022) Page Start: 843 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. (October 2014) Authors: Bookhart, Brahim K.; Haskell, Lloyd; Bamber, Luke; Wang, Maria; Schein, Jeff; Mody, Samir H. Journal: Journal of medical economics Issue: Volume 17:Number 10(2014) Page Start: 691 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study. Issue 206 (October 2021) Authors: Cohen, Alexander T.; Maraveyas, Anthony; Beyer-Westendorf, Jan; Lee, Agnes Y.Y.; Folkerts, Kerstin; Abdelgawwad, Khaled; De Sanctis, Yoriko; Fatoba, Samuel; Bamber, Luke; Bach, Miriam; Mantovani, Lorenzo G. Journal: Thrombosis research Issue: Issue 206(2021) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Issue 2 (February 2015) Authors: Prins, Martin H.; Bamber, Luke; Cano, Stefan J.; Wang, Maria Y.; Erkens, Petra; Bauersachs, Rupert; Lensing, Anthonie W.A. Journal: Thrombosis research Issue: Volume 135:Issue 2(2015) Page Start: 281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Issue 2 (February 2015) Authors: Prins, Martin H.; Bamber, Luke; Cano, Stefan J.; Wang, Maria Y.; Erkens, Petra; Bauersachs, Rupert; Lensing, Anthonie W.A. Journal: Thrombosis research Issue: Volume 135:Issue 2(2015) Page Start: 281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Patient‐reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES‐PRESERVED) study. (6th June 2017) Authors: Filippatos, Gerasimos; Maggioni, Aldo P.; Lam, Carolyn S.P.; Pieske‐Kraigher, Elisabeth; Butler, Javed; Spertus, John; Ponikowski, Piotr; Shah, Sanjiv J.; Solomon, Scott D.; Scalise, Andrea‐Viviana; Mueller, Katharina; Roessig, Lothar; Bamber, Luke; Gheorghiade, Mihai; Pieske, Burkert Journal: European journal of heart failure Issue: Volume 19:Number 6(2017) Page Start: 782 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. (May 2014) Authors: van Bellen, Bonno; Bamber, Luke; Correa de Carvalho, Francine; Prins, Martin; Wang, Maria; Lensing, Anthonie W.A. Journal: Current medical research and opinion Issue: Volume 30:Number 5(2014:May) Page Start: 829 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗